Low-grade B-cell lymphomas located around the eye present unique challenges in diagnosis and treatment. Extranodal marginal zone B-cell lymphoma is the most common lymphoma of the ocular adnexa (conjunctiva, orbit, lacrimal gland, and eyelid).
Methods
A systematic search of the relevant literature was performed. Material pertinent to the diagnosis, prognosis, pathogenesis, and treatment of extranodal marginal zone B-cell lymphoma of the ocular adnexa was identified, reviewed, and analyzed, focusing on management strategies for primary localized disease.
Results
The primary cause of extranodal marginal zone B-cell lymphoma of the ocular adnexa remains elusive, although an infectious agent is suspected. Radiotherapy is the most common initial treatment for localized disease. Initial treatment with chemotherapy, immunotherapy, and antibiotics has shown promising results, but the number of series is limited and controlled trials do not exist.
Conclusions
Although the long-term outcome of localized extranodal marginal zone B-cell lymphoma of the ocular adnexa is good, optimal treatment remains a goal. The variation in rates of local and systemic relapse among treated stage 1E tumors suggests that critical factors affecting outcomes are not fully understood. Radiotherapy is the standard of care; at this time, the evidence is insufficient to recommend chemotherapy, immunotherapy, or antibiotics for initial treatment of extranodal marginal zone B-cell lymphoma localized to the ocular adnexa. Well-controlled comparative studies are needed.
References
1.
MargoC.E., MullaZ.D.Malignant tumors of the orbit: analysis of the Florida Cancer Registry.Ophthalmology.1998; 105(1): 185–190.
2.
BonavolontàG., StrianeseD., GrassiP.An analysis of 2,480 space-occupying lesions of the orbit from 1976 to 2011.Ophthal Plast Reconstr Surg.2013; 29(7): 79–86.
3.
ShieldsJ.A., ShieldsC.L., ScartozziR.Survey of 1264 patients with orbital tumors and simulating lesions: the 2002 Montgomery Lecture, part 1.Ophthalmology.2004; 111(5): 997–1008.
4.
MargoC.E., MullaZ.D.Malignant tumors of the eyelid: a population-based study of non-basal cell and non-squamous cell malignant neoplasms.Arch Ophthalmol.1998; 116(2): 195–198.
5.
KnowlesD.M., JakobiecJ.A.Malignant lymphomas and lymphoid hyperplasias that occur in the ocular adnexa (orbit, conjunctiva, and eyelids). In: KnowlesD.M., ed. Neoplastic Hematopathology.Baltimore, MD: Williams & Wilkins; 1992: 1009–1046.
6.
MoslehiR., DevesaS.S., SchairerC.Rapidly increasing incidence of ocular non-Hodgkin lymphoma.J Natl Cancer Inst.2006; 98(13): 936–939.
7.
SjöL.D., RalfkiaerE., PrauseJ.U.Increasing incidence of ophthalmic lymphoma in Denmark from 1980 to 2005.Invest Ophthal Vis Sci.2008; 49(8): 3283–3288.
8.
JenkinsC., RoseG.E., BunceC.Histological features of ocular adnexal lymphoma (REAL classification) and their association with patient morbidity and survival.Br J Ophthamol.2000; 84(8): 907–913.
9.
MeunierJ., Lumbroso-le RouicL., Vincent-SalomonA.Ophthalmologic and intraocular non-Hodgkin's lymphoma: a large single center study of initial characteristics, natural history and prognostic factors.Hematol Oncol.2004; 22(4): 143–158.
10.
SullivanT.J., WhiteheadK., WilliamsonR.Lymphoproliferative disease of the ocular adnexa: a clinical and pathologic study with statistical analysis of 69 patients.Ophthalmic Plast Reconstr Surg.2005; 21(3): 177–188.
11.
FerryJ.A., FungC.Y., ZukerbergL.Lymphoma of the ocular adnexa: a study of 353 cases.Am J Surg Pathol.2007; 31(2): 170–184.
12.
ChoE.Y., HanJ.J., ReeJ.H.Clinicopathologic analysis of ocular adnexal lymphomas: extranodal marginal zone B-cell lymphoma constitutes the vast majority of ocular lymphomas among Koreans and affects younger patients.Am J Hematol.2003; 73(2): 87–96.
13.
CouplandS.E., HellmichM., Auw-HaedrichC.Prognostic value of cell-cycle markers in ocular adnexal lymphomas: an assessment of 230 cases.Graefes Arch Clin Exp Ophthalmol.2004; 42(2): 130–143.
14.
StefanovicA., LossosI.S.Extranodal marginal zone lymphoma of the ocular adnexa.Blood.2009; 114(3): 505–510.
15.
McKelvicP.A., McNabA., FrancisI.C.Ocular adnexal lymphoproliferative disease: a series of 73 cases.Clin Exp Ophthalmol.2001: 29(6): 387–393.
16.
LagooA.S., HaggertyC., KimY.Morphologic features of 115 lymphomas of the orbit and ocular adnexa categorized according to the World Health Organization classification: are marginal zone lymphomas in the orbit mucosa-associated lymphoid type lymphomas?Arch Pathol Lab Med.2008; 132(9): 1405–1416.
17.
HarrisN.L., JaffeE.S., DieboldJ.The World Health Organization classification of hematological and lymphoid neoplasms: report of the Clinical Advisory Committee meeting, Airlie House, Virginia, Winter 1997.J Clin Oncol.1999; 17(12): 3835–3849.
18.
RuizA., ReischlU., SwerdlowS.H.Extranodal marginal zone B-cell lymphomas of the ocular adnexa: multiparameter analysis of 34 cases including interphase molecular cytogenetics and PCR for Chlamydia psittaci.Am J Surg Path.2007; 31(5): 792–802.
19.
IsaacsonP.G., SpencerJ.Malignant lymphoma of mucosa-associated lymphoid tissue.Histopathology.1987; 11(5): 445–462.
20.
Marshall-TaylorC.E., CartunR.W., MandichD.Immunohistochemical detection of immunoglobulin light chain expression in B-cell non-Hodgkin's lymphoma using formalin-fixed paraffin-embedded tissues and a heat-induced epitope retrieval technique.Apply Immunohistochem Mol Morphol.2002; 10(3): 258–262.
21.
EvansH.L.Extranodal small lymphocytic proliferations: a clinicopathologic and immunocytochemical study.Cancer.1982; 49(1): 84–96.
22.
Ashton-KeyM., DissT.C., IsaacsonP.G.A comparative study of the value of immunohistochemistry and the polymerase chain reaction in the diagnosis of follicular lymphoma.Histopathology.1995; 27(6): 501–508.
23.
BarrenaS., AlmeidaJ., Del Carmen Garcia-MaciasM.Flow cytometry immunophenotyping of fine-needle aspiration specimens: utility in the diagnosis of classification of non-Hodgkin lymphomas.Histopathology.2011; 58(5): 906–918.
24.
EnsaniF., MehravaranS., IrvanlouG.Fine-needle aspiration cytology and flow cytometic immunophenotying of diagnosis and classification of non-Hodgkin lymphoma in comparison to histopathology.Diagn Cytopathol.2012; 40(4): 305–310.
25.
TroppanK., WenzlK., NeumeisterP.Molecular pathogenesis of MALT lymphoma.Gastroenterol Res Pract.2015; 2015: 102656.
26.
StreubelB., Simonitsch-KluppI., MüllauerL.Variable frequencies of MALT lymphoma-associated genetic aberrations in MALT lymphomas of different sites.Leukemia.2004; 18(10): 1722–1726.
27.
WhiteV.A., GascoyneR.D., McNeilB.K.Histopathologic findings and frequency of clonality by the polymerase chain reaction in ocular adnexal lymphoproliferative lesions.Mod Pathol.1996; 9(11): 1052–1061.
28.
AdachiA., TamaruJ., KanekoK.No evidence of correlation between BCL10 expression and AP12-MALT1 gene rearrangement in ocular adnexal MALT lymphoma.Path Intern.2004; 54(1): 16–25.
29.
ShararaN., HoldenJ.T., WojnoT.H.Ocular adnexal lymphoid proliferations: clinical, histologic, flow cytometric and molecular analysis of 43 cases.Ophthalmology.2003; 110(6): 1245–1254.
30.
McKelvicP.A.Ocular adnexal lymphomas: a review.Adv Anat Pathol.2010; 17(4): 251–261.
31.
GayedI., EskandariM.F., McLaughlinP.Value of positron emission tomography in staging ocular adnexal lymphomas and evaluating their response to therapy.Ophthalmic Surg Laser Imaging.2007; 38(4): 319–325.
32.
SullivanT.J., ValenzuelaA.A.Imaging features of ocular adnexal lymphoproliferative disease.Eye (Lond).2006; 20(10): 1189–1195.
33.
ValenzuelaA.A., AllenC., GrimesD.Positron emission tomography in the detection and staging of ocular adnexal lymphoproliferative disease.Ophthalmology.2006; 113(12): 2331–2337.
34.
PortellG.A., AronowM.E., RybickiL.A.Clinical characteristics of 95 patients with ocular adnexal and uveal lymphoma: treatment outcomes in extranodal marginal zone subtype.Clin Lymphoma Myeloma Leuk.2014; 14(3): 203–210.
35.
CouplandS.E., FossH.D., HaydiatA.A.Extranodal marginal zone B cell lymphoma of the uvea: an analysis of 13 cases.J Pathol.2002; 197(3): 333–340.
36.
CouplandS.E., KrauseL., DelecluseH.J.Lymphoproliferative lesions of ocular adnexa: analysis of 112 cases.Ophthalmology.1998; 105(8): 1430–1441.
37.
DecaudinD., de CremouxP., Vincent-SalomonA.Ocular adnexal lymphoma: a review of clinicopathologic features and treatment options.Blood.2006; 108(5): 1451–1460.
38.
CouplandS.E., WhiteV.A., RootmanJ.A TNM-based clinical staging system of ocular adnexal lymphomas.Arch Pathol Lab Med.2009; 133(8): 1262–1267.
RathS.Connors JM, Dolman PJ, et al. Comparison of American Joint Committee on Cancer TNM-based staging system (7th edition) and Ann Arbor classification for predicting outcome in ocular adnexal lymphoma.Orbit.2014; 33(1): 23–28.
41.
AronowM.E., PortellC.A., RybickiL.A.Ocular adnexal lymphoma: assessment of a tumor-node-metastasis staging system.Ophthalmology.2013; 120(9): 1915–1919.
42.
GraueG.F., FingerP.T., MaherE.Ocular adnexal lymphoma staging and treatment: American Joint Committee on Cancer versus Ann Arbor.Eur J Ophthalmol.2013; 23(3): 344–355.
43.
ZuccaE., BertoniF., RoggeroE.Molecular analysis of the progression from Helicobacter pylori-associated chronic gastritis to mucosa-associated lymphoid-tissue lymphoma of the stomach.N Engl J Med.1998; 338(12): 804–810.
44.
DecaudinD., DolcettiR., De CremouxP.Variable association between Chlamydophila psittaci infection and ocular adnexal lymphomas: methodological biases or true geographical variations?Anticancer Drugs.2008; 19(8): 761–765.
45.
ChanudetE., ZhouY., BaconC.M.Chlamydia psittaci is variably associated with ocular adnexa MALT lymphoma in different geographical regions.J Pathol.2006; 209(3): 344–351.
46.
FerreriA.J., GuidoboniM., PonzoniM.Evidence for an association between Chlamydia psittaci and ocular adnexal lymphomas.J Natl Cancer Inst.2004; 96(8) 586–594.
47.
HusainA., RobertsD., ProB.Meta-analysis of the association between Chlamydia psittaci and ocular adnexal lymphoma and the response of ocular adnexal lymphoma to antibiotics.Cancer.2007; 110(4): 809–815.
ChanC.C., ShenD., MochizukiM.Detection of Helicobacter pylori and Chlamydia pneumoniae genes in primary orbital lymphoma.Trans Am Ophthalmol Soc.2006; 104: 62–70.
50.
LeeS.B., YangJ.W., KimC.S.The association between conjunctival MALT lymphoma and Helicobacter pylori.Br J Ophthalmol.2008; 92(4): 534–536.
51.
SjöN.C., FoeghP., JuhlB.R.Role of Helicobacter pylori in conjunctival mucosa-associated lymphoid tissue lymphoma.Ophthalmology.2007; 114(1): 182–186.
CouplandS.E.A possible new role for Helicobacter pylori in the development of ocular adnexal lymphoma.Am J Hematol.2010; 85(9): 641–642.
54.
CohenV.M., SweetenhamJ., SinghA.R.Ocular adnexal lymphoma. What is the evidence for an infectious aetiology?Br J Ophthalmol.2008; 92(4): 446–448.
55.
MargoC.E.From Robert Koch to Bradford Hill. Chronic infection and the origins of ocular adnexal cancers.Arch Ophthalmol.2011; 129(4): 498–500.
56.
GruenbergerB., WoehrerS., TrochM.Assessing the role of hepatitis C, Helicobacter pylori and autoimmunity in MALT lymphoma of ocular adnexal in 45 Austrian patients.Acta Oncol.2008; 47(3): 355–359.
57.
LiangY., YangZ., QinB.Primary Sjögren's syndrome and malignancy risk: a systematic review and meta-analysis.Ann Rheum Dis.2014; 73(6): 1151–1156.
58.
ZinzaniP.L.The many faces of marginal zone lymphoma.Hematology Am Soc Hematol Educ Program.2012; 2012; 426–432.
59.
SmijanicM., MilosevicR., AnticD.Orbital and ocular adnexal mucosa-associated lymphoid tissue (MALT) lymphomas: a single-center 10-year experience.Med Oncol. 2013 30(4): 722–730.
60.
HaradaK., MurakamiN., KitaguchiM.Localized ocular adnexal mucosa-associated lymphoid tissue lymphoma treated with radiation therapy: a long-term outcome in 86 patients with 104 treated eyes.Int J Radiat Oncol Biol Phys.2014; 88(3): 650–654.
61.
TuncerS., TanyildizB., BasaranM.Systemic rituximab immunotherapy in the management of primary ocular adnexal lymphoma: single institution experience.Curr Eye Res.2015; 40(8): 780–785.
62.
KiesewetterB., LukasJ., KucharA.Clinical features, treatment and outcome of mucosa-associated lymphoid tissue (MALT) lymphoma of the ocular adnexa: a single center experience of 60 patients.PLoS One.2014; 9(7): e104004.
63.
MartinetS., OzsahinM., BelkacémiY.Outcome and prognostic factors in orbital lymphoma: a rare cancer network study on 90 consecutive patients treated with radiotherapy.Int J Rad Oncol Biol Phys.2003; 55(4): 892–898.
64.
UnoT., IsobeK., ShikamaN.Radiotherapy for extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue originating in the ocular adnexa: a multi-institutional, retrospective review of 50 patients.Cancer.2003; 98(4): 865–871.
65.
TanimotoK., KanekoA., SuzukiS.Primary ocular adnexal MALT lymphoma: a long-term follow-up study of 114 patients.Jpn J Clin Oncol.2007; 37(5): 337–344.
66.
KaoS.C., KauH.C., TsaiC.C.Lacrimal gland extranodal marginal zone B-cell lymphoma of MALT-type.Am J Ophthalmol.2007; 143(2): 311–315.
67.
FerreriA.J., PonzoniM., MartinelliG.Rituximab in patients with mucosa-associated lymphoid tissue type lymphoma of the ocular adnexa.Haematologica.2005; 90(11): 1578–1579.
68.
SongE-K, KimS-Y, KimT.M.Efficacy of chemotherapy as a first-line treatment in ocular adnexal extranodal marginal zone B-cell lymphoma.Ann Oncol.2008; 19(2): 242–246.
69.
Ben SimonG.J., CheungN., McKelvieP.Oral chlorambucil for extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue of the orbit.Ophthalmology.2006; 113(7): 1209–1213.
70.
HashimotoN., SasakiR., NishimuraH.Long-term outcome and patterns of failure of primary ocular adnexal mucosa-associated lymphoid tissue lymphoma treated with radiotherapy.Int J Radiat Oncol Biol Phys.2012; 82(4): 1509–1514.
71.
PaikJ.S., ChoW.K., LeeS.E.Ophthalmologic outcomes after chemotherapy and/or radiotherapy in non-conjunctival ocular adnexal MALT lymphoma.Ann Hematol.2012; 91(9): 1393–1401.
72.
YoonJ.S., MaK.T., KimS.J.Prognosis for patients in a Korean population with ocular adnexal lymphoproliferative lesions.Ophthal Plast Reconst Surg.2007; 23(2): 94–99.
73.
NamH., AhnY.C., KimY.D.Prognostic significance of anatomic subsites: results of radiation therapy for 66 patients with localized orbital marginal zone B cell lymphoma.Radiation Oncol.2009; 90(2): 236–241.
74.
SullivanT.J., GrimesD., BunceI.Monoclonal antibody treatment of orbital lymphoma.Ophthalmic Plast Reconstr Surg.2004; 20(2): 103–106.
75.
RussellW., HerskovicA., GessertD.Ocular adnexal MALTomas: case series of patients treated with primary radiation.Clin Adv Hematol Oncol.2013; 11(4): 209–214.
76.
MatsuoT., YoshinoT.Long-term follow-up results of observation or radiation for conjunctival lymphoma.Ophthalmology.2004; 111(6): 1233–1237.
77.
LimS.H., KangM., SonJ.Extranodal marginal zone B cell lymphoma of mucosa-associated lymphoid tissue type of the ocular adnexa: retrospective single institution review of 95 patients.Indian J Ophthlamol.2011; 59(4): 273–277.
78.
HanJ.J., KimT.M., JeonY.K.Long-term outcomes of first-line treatment with doxycycline in patients with previously untreated ocular adnexal marginal zone B cell lymphoma.Ann Hematol.2015; 94(4): 575–581.
79.
WoolfD.K., KuhanH., ShoffrenO.Outcome of primary lymphoma of the ocular adnexal (orbital lymphoma) treated with radiotherapy.Clin Oncol (R Coll Radiol).2015; 27: (3): 153–159.
80.
GodaJ.S., LeL.W., LapperriereN.J.Localized orbital mucosa-associated lymphoid tissue lymphoma managed with primary radiation therapy: efficacy and toxicity.Int J Radiat Oncol Biol Phys.2011; 81(4): e659–e666.
81.
TranK.H., CampbellB.A., FuaT.Efficacy of low dose radiotherapy for primary orbital marginal zone lymphoma.Leuk Lymphoma.2013; 54(3): 491–496.
82.
SonS.H., ChoiB.O., KimG.W.Primary radiation therapy in patients with localized orbital marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma).Int J Radiat Oncol Biol Phys.2010; 77(1): 86–91.
83.
SuhC.O., ShimS.J., LeeS.W.Orbital marginal zone B-cell lymphoma of MALT: radiotherapy results and clinical behavior.Radiat Oncol Biol.2006; 65(1): 228–233.
84.
LeQ.T., EulauS.M., GeorgeT.I.Primary radiotherapy for localized orbital MALT lymphoma.Int J Radiat Oncol Biol Phys.2002; 52(3): 657–663.
85.
FerreriA.J., PonzoniM., GuidoboniM.Bacteria-eradicating therapy with doxycycline in ocular adnexal MALT lymphoma: a multicenter prospective trial.J Natl Cancer Inst. 2006 98(19): 1375–1382.
86.
TanimotoK., KanekoA., SuzukiS.Long-term follow-up results of no initial therapy for ocular adnexal MALT lymphoma.Ann Oncol.2006; 17(1) 135–140.
87.
FerreriA.J., GoviS., PasiniE.Chlamydophila psittaci eradication with doxycycline as first-line targeted therapy for ocular adnexae lymphoma: final results of an international phase II trial.J Clin Oncol.2012; 30(24): 2988–2994.
88.
GoviS., DogniniG.P., LicataG.Six-month oral clarithromycin is safe and active in extranodal marginal zone B-cell lymphomas: final results of a single-centre phase II trial.Br J Haematol.2010: 150(2): 226–248.
89.
WahlR.L., JaceneH., KasamonY.From RECIST to PERCIST: evolving consideration for PET response criteria in solid tumors.J Nucl Med.2009; 50(suppl 1): 122S–50S.
90.
JungS.K., PaikJ.S., JungS.E.Suggestion of response evaluation criteria in patients with ocular adnexal mucosa-associated lymphoid tissue lymphoma (OAML).Am Hematol.2015; 94(7): 1185–1193.
